Free public records show Shanghai Huilun Pharmaceutical Co., Ltd. in 1 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Shanghai Huilun Pharmaceutical Co., Ltd. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
4 active studies led by Shanghai Huilun Pharmaceutical Co., Ltd., of 5 in all
Source: ClinicalTrials.gov, Studies with Shanghai Huilun Pharmaceutical Co., Ltd. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Studies Shanghai Huilun Pharmaceutical Co., Ltd. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with Shanghai Huilun Pharmaceutical Co., Ltd. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show Shanghai Huilun Pharmaceutical Co., Ltd.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Shanghai Huilun Pharmaceutical Co., Ltd. is in.
Stories on the topics Shanghai Huilun Pharmaceutical Co., Ltd. works in.
170 of 194 WHO member states report use of traditional medicine. Herbal products are popular, but quality and…
Read
About 3 in 10 US adults sleep less than 7 hours. Melatonin helps with jet lag and shift work, but its effect…
Read
The FDA has approved one cannabis-derived medicine, Epidiolex, for rare epilepsies, and three synthetic…
ReadSearch all reports for Shanghai Huilun Pharmaceutical Co., Ltd. All companies